Defining Chronic Graft vs Host Disease (GvHD)
Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.
Novel Agents in Acute GvHD
Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.
Steroid Refractory Acute GvHD and REACH Trials
An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.
Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options
Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.
Future of Acute GvHD Prevention
A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.
Clinical Implications of the Phase III BMT CTN 1703 Trial
Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice
Regimens Used for GvHD Prevention
A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.
An Overview of Graft vs Host Disease (GvHD)
Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.
Unmet Needs in GVHD Management
Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.
Supportive Care for Steroid-Refractory Chronic GVHD Treatment
Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.
Clinical Manifestations of Chronic GVHD
Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.
Future of Steroid-Refractory Chronic GVHD Treatment
Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.
Treatment Selection for Steroid-Refractory GVHD
Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.
Steroid-Refractory Chronic GVHD: Management Strategies
Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.
Steroids for First-Line Treatment of Chronic GVHD
Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.
Overview of Steroid-Refractory Acute GVHD
Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.
Evolution of Treatment for Acute GVHD
Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.
Goals of Therapy for Acute GVHD Treatment
Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.
Impact of GVHD on Patient Outcomes
Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.
ASH 2021 Updates for GVHD Prophylaxis
Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.
Selecting GVHD Prophylaxis
Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.
Challenges in Early Detection of GvHD
Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.
Overview of Graft-vs-Host Disease (GVHD)
Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512